14 recruiting, 3 completed, 2 active not recruiting, 2 not yet recruiting. 15 Phase 1, 10 Phase 2, 7 Phase 3.
Follow Revolution Medicines, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer Daraxonrasib - Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc) | Phase 2 | Not yet recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 55 | 2026-11-01 | 2026-08-28 |
| First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer SNV1521, daraxonrasib - Pancreatic Cancer, Pancreatic Acinar Carcinoma | Phase 1 | Not yet recruiting | ParVation Therapeutics, Inc. | 40 | 2026-09-01 | 2026-08-10 |
| Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma daraxonrasib, gemcitabine, nab-paclitaxel - Pancreatic Cancer, Pancreatic Cancer Metastatic | Phase 3 | Recruiting | Revolution Medicines, Inc. | 400 | 2026-08-28 | 2026-10-16 |
| Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC zoldonrasib, Placebo, pembrolizumab - NSCLC, Non-small Cell Lung Cancer | Phase 3 | Recruiting | Revolution Medicines, Inc. | 430 | 2026-08-14 | 2026-08-20 |
| Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) Zoldonrasib, Placebo, Oxaliplatin - Pancreatic Cancer, Pancreatic Cancer Metastatic | Phase 3 | Recruiting | Revolution Medicines, Inc. | 670 | 2026-05-22 | 2026-10-13 |
| Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma daraxonrasib, gemcitabine, nab-paclitaxel - Pancreatic Cancer, Pancreatic Cancer Metastatic | Phase 3 | Recruiting | Revolution Medicines, Inc. | 900 | 2026-03-09 | 2026-10-02 |
| Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors Daraxonrasib, Elironrasib, Zoldonrasib - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 370 | 2026-01-30 | 2026-08-03 |
| Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors RMC-5127, daraxonrasib, cetuximab - Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) | Phase 1 | Recruiting | Revolution Medicines, Inc. | 574 | 2026-01-08 | 2026-09-17 |
| Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) daraxonrasib - Pancreatic Cancer, PDAC | Phase 3 | Recruiting | Revolution Medicines, Inc. | 500 | 2025-12-15 | 2026-09-23 |
| Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients TNG462, RMC-9805, RMC-6236 - PDAC, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Tango Therapeutics, Inc. | 183 | 2025-05-31 | 2026-05-14 |
| Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) daraxonrasib, docetaxel - NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer | Phase 3 | Recruiting | Revolution Medicines, Inc. | 590 | 2025-05-06 | 2026-09-29 |
| Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) RMC-6236, Gemcitabine, nab-paclitaxel - Pancreatic Cancer, PDAC | Phase 3 | Active not recruiting | Revolution Medicines, Inc. | 500 | 2024-10-16 | 2026-06-02 |
| Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors RMC-6236, mFOLFOX6 regimen, bevacizumab - Colorectal Cancer, CRC | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 1130 | 2024-05-24 | 2026-09-22 |
| Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC RMC-6291, RMC-6236, Pembrolizumab - Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 616 | 2024-01-18 | 2026-10-19 |
| Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors Elironrasib, Daraxonrasib - Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 534 | 2023-11-14 | 2026-09-22 |
| Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors RMC-9805, RMC-6236 - Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) | Phase 1 | Recruiting | Revolution Medicines, Inc. | 604 | 2023-09-07 | 2026-06-03 |
| RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma RMC-5552 - Glioblastoma, Recurrent Glioblastoma | Phase 1 | Terminated | Nicholas Butowski | 7 | 2023-04-03 | 2026-05-06 |
| Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors RMC-6291 - Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) | Phase 1 | Active not recruiting | Revolution Medicines, Inc. | 222 | 2022-09-19 | 2026-05-15 |
| Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS RMC-6236 - Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 754 | 2022-05-31 | 2026-05-15 |
| Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies RMC-4630, Sotorasib - Non-Small Cell Lung Cancer | Phase 2 | Completed | Revolution Medicines, Inc. | 47 | 2021-12-30 | 2026-01-06 |
Showing 20 of 25. Sign in to see all of them.
Pancreatic Neoplasms (14) · Carcinoma, Non-Small-Cell Lung (13) · Lung Neoplasms (13) · Gastrointestinal Neoplasms (9) · Colorectal Neoplasms (8) · Neoplasms (7) · Bronchial Neoplasms (6) · Lung Diseases (6) · Neoplasm Metastasis (6) · Neoplasms by Site (6) · Respiratory Tract Diseases (6) · Respiratory Tract Neoplasms (6) · Thoracic Neoplasms (6) · Ovarian Neoplasms (5) · Carcinoma, Pancreatic Ductal (4)
130-nm albumin-bound paclitaxel (5) · Gemcitabine (5) · Carboplatin (3) · Cetuximab (3) · Cisplatin (3) · Pemetrexed (3) · pembrolizumab (3) · Fluorouracil (2) · Irinotecan (2) · Leucovorin (2) · Oxaliplatin (2) · Bevacizumab (1) · Docetaxel (1) · EIF4EBP1 protein, human (1) · Mechanistic Target of Rapamycin Complex 1 (1)
United States (24) · Spain (9) · Italy (8) · South Korea (8) · France (7) · Germany (7) · Australia (6) · Taiwan (6) · Puerto Rico (5) · United Kingdom (5) · Japan (4) · Netherlands (4) · Singapore (3) · Austria (2) · Belgium (2)
Maxim Pimpkin, MD, PhD (1) · Nicholas Butowski, MD (1) · Nilo Azad, MD (1) · Revolution Medicines (1) · Revolution Medicines, Inc (1)
PMID 40056080, PMID 37590355, PMID 38589574, PMID 38593348, PMID 40705880, PMID 41056387, PMID 42090791, PMID 42223072, PMID 42685317
P50CA097257 (1)